Feature | March 12, 2014

Partnership Investigates Remote Robotic PCI at Rural Hospitals

Corindus CorPath Robotic Navigation Telemedicine Telecardiology Cath Lab

March 12, 2014 — For patients living in rural areas, life-saving procedures such as an angioplasty may only be available at a facility more than 200 miles away. To bridge this distance, Corindus Vascular Robotics is partnering with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a feasibility study for a remote robotic systems cath lab telecardiology program. 

Following the feasibility study, the remote robotics program is intended to potentially empower an interventional cardiologist at a major center to robotically control the movement of interventional devices at a remote facility. This could offer patients located in rural areas the high-quality heart care and treatment currently available only at heart centers in major metropolitan areas. The first phase of the program aims to understand what is required to make remote robotics successful. The development of the program will proceed based on those findings.

With funding from The Leona M. and Harry B. Helmsley Charitable Trust, Corindus and Sanford Health will pursue pioneering remote capabilities for robotic-assisted percutaneous coronary intervention (PCI).

CorPath is an U. S. Food and Drug Administration (FDA)-cleared technology. It enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Physicians sit in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows the cardiologist to advance stents and guidewires millimeter-by-millimeter using joysticks and touchscreen controls. The remote robotics program is intended to extend the capability of CorPath to not just perform angioplasty in the same cath lab, but in labs hundreds of miles away. 

For more information: www.corindus.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now